CY1119560T1 - Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας - Google Patents
Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιαςInfo
- Publication number
- CY1119560T1 CY1119560T1 CY20171101188T CY171101188T CY1119560T1 CY 1119560 T1 CY1119560 T1 CY 1119560T1 CY 20171101188 T CY20171101188 T CY 20171101188T CY 171101188 T CY171101188 T CY 171101188T CY 1119560 T1 CY1119560 T1 CY 1119560T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- disorder
- adoptive
- reduce
- mental health
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Στο παρόν περιγράφονται συνθέσεις, χρήσεις, κιτ και μέθοδοι για μείωση αδηφαγικής διαταραχής ή ψυχαναγκαστικής υπερφαγίας. Οι μέθοδοι μπορεί να περιλαμβάνουν χορήγηση αποτελεσματικού συνδυασμού μιας δοσολογίας μπουπροπιόνης ή φαρμακευτικώς αποδεκτού άλατος αυτής και μιας δοσολογίας ναλτρεξόνης ή φαρμακευτικώς αποδεκτού άλατος αυτής. Οι μέθοδοι μπορεί να περιλαμβάνουν την πιστοποίηση ενός ασθενούς που είναι υπέρβαρος ή παχύσαρκος και την παροχή αποτελεσματικού συνδυασμού μπουπροπιόνης και ναλτρεξόνης στον ασθενή. Οι μέθοδοι μπορεί να περιλαμβάνουν μείωση του αριθμού επεισοδίων αδηφαγικής διαταραχής ή ψυχαναγκαστικής υπερφαγίας. Οι μέθοδοι μπορεί να περιλαμβάνουν μείωση της σοβαρότητας των επεισοδίων αδηφαγικής διαταραχής ή ψυχαναγκαστικής υπερφαγίας.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41935410P | 2010-12-03 | 2010-12-03 | |
| PCT/US2011/063170 WO2012075453A1 (en) | 2010-12-03 | 2011-12-02 | Methods for reducing binge or compulsive eating |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119560T1 true CY1119560T1 (el) | 2018-03-07 |
Family
ID=46172302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20171101188T CY1119560T1 (el) | 2010-12-03 | 2017-11-14 | Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US20130252995A1 (el) |
| EP (1) | EP2646011B1 (el) |
| JP (1) | JP2014508717A (el) |
| KR (1) | KR20140035319A (el) |
| CN (1) | CN103298462A (el) |
| AR (2) | AR084093A1 (el) |
| AU (3) | AU2011336298B2 (el) |
| BR (1) | BR112013015957B1 (el) |
| CA (1) | CA2819003A1 (el) |
| CL (1) | CL2013001565A1 (el) |
| CY (1) | CY1119560T1 (el) |
| DK (1) | DK2646011T3 (el) |
| ES (1) | ES2647232T3 (el) |
| HR (1) | HRP20171678T1 (el) |
| HU (1) | HUE034641T2 (el) |
| IL (1) | IL226483A0 (el) |
| LT (1) | LT2646011T (el) |
| MX (1) | MX350304B (el) |
| NO (1) | NO2646011T3 (el) |
| PL (1) | PL2646011T3 (el) |
| PT (1) | PT2646011T (el) |
| RS (1) | RS56548B1 (el) |
| RU (1) | RU2620913C2 (el) |
| SI (1) | SI2646011T1 (el) |
| TW (2) | TWI536986B (el) |
| WO (1) | WO2012075453A1 (el) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
| BRPI0618918B8 (pt) | 2005-11-22 | 2021-05-25 | Nalpropion Pharmaceuticals Llc | uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| MX2010012909A (es) | 2008-05-30 | 2011-02-25 | Orexigen Therapeutics Inc | Metodos para tratamiento de condiciones de grasa visceral. |
| AU2011203867B2 (en) | 2010-01-11 | 2015-12-03 | Nalpropion Pharmaceuticals Llc | Methods of providing weight loss therapy in patients with major depression |
| EP2858640B1 (en) | 2012-06-06 | 2020-03-25 | Nalpropion Pharmaceuticals LLC | Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2197250C2 (ru) * | 2000-10-30 | 2003-01-27 | Соколовский Сергей Ростиславович | Способ лечения наркоманий |
| ES2303085T3 (es) | 2003-04-29 | 2008-08-01 | Orexigen Therapeutics, Inc. | Composiciones que afectan a la perdida de peso. |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| KR20190042766A (ko) | 2006-11-09 | 2019-04-24 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
| MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
| GB2447949B (en) * | 2007-03-29 | 2010-03-31 | Renasci Consultancy Ltd | A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission |
| US8318813B2 (en) * | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| US20100317572A1 (en) * | 2007-12-20 | 2010-12-16 | Neurosearch A/S | Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound |
| AU2011326173B2 (en) * | 2010-11-08 | 2015-08-27 | Omeros Corporation | Treatment of addiction and impulse-control disorders using PDE7 inhibitors |
-
2011
- 2011-12-02 LT LTEP11844637.6T patent/LT2646011T/lt unknown
- 2011-12-02 AR ARP110104511A patent/AR084093A1/es not_active Application Discontinuation
- 2011-12-02 SI SI201131336T patent/SI2646011T1/en unknown
- 2011-12-02 PT PT118446376T patent/PT2646011T/pt unknown
- 2011-12-02 JP JP2013542227A patent/JP2014508717A/ja active Pending
- 2011-12-02 EP EP11844637.6A patent/EP2646011B1/en active Active
- 2011-12-02 CN CN2011800595435A patent/CN103298462A/zh active Pending
- 2011-12-02 US US13/991,372 patent/US20130252995A1/en not_active Abandoned
- 2011-12-02 DK DK11844637.6T patent/DK2646011T3/da active
- 2011-12-02 ES ES11844637.6T patent/ES2647232T3/es active Active
- 2011-12-02 CA CA2819003A patent/CA2819003A1/en not_active Abandoned
- 2011-12-02 RU RU2013127420A patent/RU2620913C2/ru active
- 2011-12-02 HU HUE11844637A patent/HUE034641T2/en unknown
- 2011-12-02 NO NO11844637A patent/NO2646011T3/no unknown
- 2011-12-02 AU AU2011336298A patent/AU2011336298B2/en active Active
- 2011-12-02 KR KR1020137017316A patent/KR20140035319A/ko not_active Application Discontinuation
- 2011-12-02 RS RS20171107A patent/RS56548B1/sr unknown
- 2011-12-02 BR BR112013015957-0A patent/BR112013015957B1/pt active IP Right Grant
- 2011-12-02 TW TW100144461A patent/TWI536986B/zh active
- 2011-12-02 TW TW105105528A patent/TW201735912A/zh unknown
- 2011-12-02 WO PCT/US2011/063170 patent/WO2012075453A1/en active Application Filing
- 2011-12-02 MX MX2013006070A patent/MX350304B/es active IP Right Grant
- 2011-12-02 PL PL11844637T patent/PL2646011T3/pl unknown
-
2013
- 2013-05-21 IL IL226483A patent/IL226483A0/en unknown
- 2013-05-31 CL CL2013001565A patent/CL2013001565A1/es unknown
-
2017
- 2017-04-27 AU AU2017202793A patent/AU2017202793B2/en active Active
- 2017-11-02 HR HRP20171678TT patent/HRP20171678T1/hr unknown
- 2017-11-14 CY CY20171101188T patent/CY1119560T1/el unknown
-
2018
- 2018-06-04 AU AU2018203921A patent/AU2018203921A1/en not_active Abandoned
-
2021
- 2021-06-02 US US17/336,546 patent/US20210283126A1/en active Pending
- 2021-12-23 AR ARP210103652A patent/AR124497A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119560T1 (el) | Μεθοδοι για μειωση αδηφαγικης διαταραχης ή ψυχαναγκαστικης υπερφαγιας | |
| CY1120297T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου και χρησεις αυτων | |
| GT200800250A (es) | Arilimidazolonas y ariltriazolonas sustituidas como inhibidores de receptores de vasopresina | |
| ECSP12012326A (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| ME01532B (me) | Jedinjenja | |
| GT200900230A (es) | 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso | |
| ECSP13012611A (es) | Derivados de pirazol-aminopirimidina como moduladores de la lrrk2 | |
| CY1120058T1 (el) | Συνδυασμοι ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα-2 αδρενεργικου υποδοχεα | |
| CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| UY33890A (es) | Nuevas azaindolilfenil sulfonamidas como inhibidores de serina/ treonina cinasa | |
| UY33616A (es) | Compuestos con estructura de imidazotriazinona | |
| JP2011006431A5 (el) | ||
| DOP2012000006A (es) | Agonista de gpr119 | |
| CR20110509A (es) | Composicion farmaceutica | |
| CR11818A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
| UY31314A1 (es) | Amidas heterociclicas y sus métodos de uso-976 | |
| CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
| EA201390977A1 (ru) | Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона | |
| CL2008002368A1 (es) | Uso de gaboxadol para preparar un medicamento util en el tratamiento de la depresion en pacientes que tienen uno o mas marcadores inflamatorios elevados o anormales. | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| CY1123614T1 (el) | Μεθοδος θεραπειας δυσκινησιας | |
| BR112013009970A2 (pt) | método para determinar uma característica do ritmo circadiano de um paciente. | |
| CO6280470A2 (es) | Bis-piridilpiridonas como antaginistas del receptor 1 de la hormona concentradora de la melanina | |
| UY32822A (es) | Composiciones farmacéuticas para el tratamiento de cáncer y otras enfermedades o trastornos | |
| EA202091356A1 (ru) | A2a АНТАГОНИСТЫ КАК УСИЛИТЕЛИ КОГНИТИВНОЙ И МОТОРНОЙ ФУНКЦИЙ |